Guerbet Financial Agenda for 2025
Guerbet, a global leader in medical imaging, has unveiled its financial agenda for 2025, outlining important upcoming dates for investors and stakeholders. As a pioneer in providing contrast agents and solutions for medical imaging, Guerbet (Paris: GBT) continues to innovate and adapt in a rapidly evolving health landscape.
Key Upcoming Dates
The financial calendar is significant to both investors and the healthcare industry. Here are the key dates Guerbet has highlighted for 2025:
Annual Revenue Release
Guerbet will announce its annual revenue for 2024 on February 6, 2025, after trading hours. This release is crucial for stakeholders as it sets the tone for the company's financial performance.
Annual Results Announcement
The much-anticipated annual results for 2024 will be disclosed on March 25, 2025. This report will provide a comprehensive overview of the company's successes and challenges over the past year.
First Quarter Revenue
Another important date is April 24, 2025, when Guerbet will share its first-quarter revenue report for 2025. This quarterly update is important for evaluating the immediate results and trajectories of the company.
Annual Shareholders’ Meeting
Guerbet is set to hold its Annual Shareholders' Meeting on May 23, 2025. This event will be an opportunity for shareholders to engage with company leadership and discuss strategic directions.
Financial Reviews for the Year
Moving through the year, Guerbet will publish additional financial reports:
Second Quarter Revenue
The second-quarter revenue report will be announced on July 24, 2025. This interim evaluation will offer insights into the company's performance during the first half of the calendar.
First Half Results
The results for the first half of 2025 will be shared on September 22, 2025. This report will provide a deeper look at how the company is tracking against its objectives.
Third Quarter Revenue
Finally, the revenue for the third quarter will be announced on October 23, 2025. This marks a pivotal moment in assessing the company's annual performance and strategies moving forward.
About Guerbet
Guerbet excels in enhancing healthcare through innovative medical imaging solutions. Employing over 2,600 dedicated professionals across the globe, the company focuses heavily on research and development, allocating 10% of its sales revenue toward this endeavor. This commitment to innovation over its 95-year history has cemented Guerbet as a leader in its field.
In recent years, Guerbet has significantly expanded its portfolio of pharmaceutical products, medical devices, and advanced AI-driven solutions aimed at optimizing diagnostic and interventional imaging. The company's dedication to quality and innovation has resulted in revenues of €786 million in 2023, demonstrating resilience and a strong market presence.
As Guerbet continues to grow, it emphasizes the importance of strong relationships in the healthcare sector, believing that better connections can lead to improved health outcomes.
Contact Information
For inquiries, reach out to:
Guerbet
Jérôme Estampes, Chief Financial Officer: +33 1 45 91 50 00 / jerome.estampes@guerbet.com
Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / christine.allard@guerbet.com
Seitosei.Actifin
Marianne Py, Financial Communication: +33 1 80 48 25 31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Press: +33 1 56 88 11 19 / jennifer.jullia@seitosei-actifin.com
Frequently Asked Questions
What is the purpose of Guerbet's financial agenda for 2025?
The financial agenda outlines key publishing dates for annual and quarterly reports, providing stakeholders with crucial financial information.
Why is the shareholders' meeting important?
The Annual Shareholders' Meeting allows investors to engage with company leaders and influence the strategic direction of Guerbet.
What does Guerbet focus on in its research and development?
Guerbet invests heavily in R&D to innovate in medical imaging technologies, ultimately enhancing patient outcomes in healthcare.
When are the other financial report announcements scheduled?
Aside from the annual results, Guerbet has scheduled quarterly revenue releases throughout 2025, with important financial reviews each quarter.
How has Guerbet performed financially recently?
Guerbet reported €786 million in revenue for 2023, showcasing its strong market presence and commitment to innovation in healthcare.
